CACNA1B
Voltage-dependent N-type calcium channel subunit alpha-1B
As of the edition of 20 October 2026, CACNA1B (voltage-dependent N-type calcium channel subunit alpha-1B, UniProt Q00975) has 7 drugs tested at it and 13 companies on the list, 3 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q00975
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 7
- Disease areas
- Nervous system; Mental health; Cancer; Blood and lymph; Chemically induced; Heart and blood vessels; Immune system; Inherited and neonatal
- Registered trials of its drugs
- 220
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Went quiet | 3 |
| Status not established | 1 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Levetiracetam | Marketed | Phase 4 | none listed |
| Ziconotide | Marketed | Phase 4 | none listed |
| CNV2197944 | Went quiet | Phase 2 | none listed |
| Ralfinamide | Went quiet | Phase 3 | none listed |
| YHD1119 | Status not established | Phase 1 | none listed |
| Z160 | Went quiet | Phase 2 | none listed |
| Ziconotide acetate | Marketed | No phase stated | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 3 |
| Engaged | 5 |
| Undetermined | 2 |
| Total on the list | 13 |
| Company | Route |
|---|---|
| Esteve Pharmaceuticals | Route B |
| Aché Laboratórios Farmacêuticos | Route B |
| Newron Pharmaceuticals | Route A |
The other 10 companies at CACNA1B
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at CACNA1B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.